CureVac (NASDAQ:CVAC – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Analyst Ratings
This is a breakdown of recent recommendations for CureVac and Longeveron, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
Longeveron has a consensus price target of $80.00, indicating a potential upside of 2,746.98%. Given Longeveron’s stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than CureVac.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
| Longeveron | $1.20 million | 7.47 | -$22.70 million | ($9.90) | -0.28 |
CureVac has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500.
Insider & Institutional Ownership
17.3% of CureVac shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 2.1% of CureVac shares are held by company insiders. Comparatively, 7.4% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares CureVac and Longeveron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CureVac | 199.92% | -23.03% | -19.09% |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
Summary
CureVac beats Longeveron on 10 of the 14 factors compared between the two stocks.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
